---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-214706"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2023-08-17T23:59:59+00:00"
generated_at: "2026-06-11T07:39:01.868521+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Selecta posts Q2 net loss of $11.4M; suspends pipeline investment to focus on SEL-212 BLA filing in 1H 2024

## Summary
- Net loss of $11.4M ($0.07/share) vs net income of $8.6M ($0.06) in Q2 2022; collaboration revenue fell to $5.2M from $39.3M.
- Cash, equivalents, restricted cash, marketable securities $115.0M as of June 30, 2023; expected to fund operations into 2027.
- BLA submission for SEL-212 (chronic refractory gout) on track for 1H 2024; eligible for up to $615M in remaining milestone payments from Sobi.
- Halting further investment in pipeline assets including ImmTOR-IL; evaluating licensing/corporate development for pipeline programs.
- Partnership with Astellas for Xork IgG protease in LOPD continues; Xork designed to expand gene therapy access.

## SEC filing metadata
- accession: 0001193125-23-214706
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2023-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/0001193125-23-214706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/d541263d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-214706
- JSON: https://secwatch.observer/filing/0001193125-23-214706.json
- Plain text: https://secwatch.observer/filing/0001193125-23-214706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.